Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: Analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo

Blood

Volumn 99, Issue 4, 2002, Pages 1356-1363

  Zhou, Da Cheng ^a,b   Kim, Soon H ^a,b   Ding, Wei ^a,b   Schultz, Cynthia ^a,b   Warrell Jr , Raymond P ^a,b   Gallagher, Robert E ^a,b,c  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; HUM 195; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD33; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CELL DIFFERENTIATION; CELL ISOLATION; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; ENHANCER REGION; ENZYME INHIBITION; GENE CONTROL; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; LIGAND BINDING; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DOMAIN; TREATMENT OUTCOME;

EID: 0037082488     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.4.1356     Document Type: Article

References (45)

1. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients
2. Resistance to all-trans-retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro sensitivity and cellular retinoic acid binding protein levels in leukemic cells
3. All-transretinoic acid for acute promyelocytic leukemia: Results of the New York study
4. 9-cis retinolic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia
5. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy
6. Mutations in the E-domain of RARα portion of the PML/RARα chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia
7. 3 sensitive relapse acute promyelocytic leukemia
8. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation
9. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers
10. PML/RARα fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyetocytic phenotype
11. Nuclear receptor coregulators: Cellular and molecular biology
12. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
13. Role of the histone deacetylase complex in acute promyelocytic leukemia
14. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications
15. Chromatin remodeling and leukemia: New therapeutic paradigms
16. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
17. Initial clinical evaluation of "transcription therapy" for cancer: All-trans retinoic acid and phenylbutyrate
18. Isolation and binding characteristics of nuclear retinoic acid receptors
19. Characterization of acute promyelocytic leukemia cases with PML-RARα break/fusion sites in PML exon 6: Identification of a subgroup with decreased in vitro responsiveness to all-trans retinolic acid
20. Cell line AP-1060 with novel phenotypic and genotypic features established from acute promyelocytic leukemia (APL) patient clinically-resistant to all-trans retinoic acid (RA) and arsenic trioxide (ATO)
21. Characterization of the retinoid binding properties of the major fusion products present acute promyelocytic leukemia cells
22. Altered ligand binding and transcriptional regulation by mutations in the PML/RARα ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia
23. Proposed revised criteria for the classification of acute myeloid leukemia
24. Infrequent alterations of the RARα gene in acute myelogenous leukemias, retinoic acid-resistant acute promyelocytic leukemias, myelodysplastic syndromes, and cell lines
25. Therapy of molecular relapse in acute promyelocytic leukemia
26. Predictive value of automated, quantitative real-time RT-PCR performed at the end of consolidation of acute promyelocytic leukemia: A SWOG, CALGB and ECOG Intergroup Study (INT-0129)
27. Syndrome of resistance to thyroid hormone: Insights into thyroid hormone action
28. A role for helix 3 of the TRβ ligand-binding domain in coactivator recruitment identified by characterization of a tiered cluster of mutations in resistance to thyroid hormone
29. A mutated PML/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, block RARA and wild-type PML/RARA transcriptional activities
30. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity
31. Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor-alpha
32. Resistance to thyroid hormone (RTH) syndrome reveals novel determinants regulating interaction of T3 receptor with corepressor
33. Crystal structure of the RAR-γ ligand binding domain bound to all-trans retinoic acid
34. Identification of amino acids critical for the DNA binding and dimerization properties of the human retinoic acid receptor alpha. Importance of lysine 360 lysine 365 and valine 361
35. Analysis of the ligand-binding domain of human retinoic acid a by site-directed mutagenesis
36. Differential role of homologous positively charged amino acid residues for ligand binding in retinoic acid receptor α compared with retinoic acid receptor β
37. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300
38. Constitutive degradation of PML/RARα through the pro-teasome pathway mediates retinoic acid resistance
39. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic persistent NB4 cells
40. Relationship between degradation of PML-RARα and differentiation
41. The molecular biology of acute promyelocytic leukemia
42. Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies and implications
43. Identification of a receptor for the morphogen retinoic acid
44. Novel mutation in the PML/RARalpha chimeric gene exhibit dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia